$8.24
6.32%
Nasdaq, Jun 28, 10:00 pm CET
ISIN
US53630X1046
Symbol
LPCN
Sector
Industry

Lipocine, Inc. Share price

$8.24
+1.61 24.28% 1M
+5.40 190.14% 6M
+5.45 195.34% YTD
+3.51 74.21% 1Y
-16.24 66.34% 3Y
-24.91 75.14% 5Y
-95.46 92.05% 10Y
Nasdaq, Closing price Fri, Jun 28 2024
ISIN
US53630X1046
Symbol
LPCN
Sector
Industry

Key figures

Market capitalization $44.07m
Enterprise Value $19.44m
PER (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
EV/Sales (TTM) EV/Sales 2.53
P/S ratio (TTM) P/S ratio 5.75
P/B ratio (TTM) P/B ratio 1.83
Sales growth (TTM) Sales growth 1,282.40%
Turnover (TTM) Turnover $7.67m
EBIT (operating result TTM) EBIT $-7.41m
Free cash flow (TTM) Free cash flow $-5.54m
Cash position $24.63m
EPS (TTM) EPS $-1.72
P/E ratio expected negative
P/S ratio expected 4.92
EV/Sales expected 2.17
Short interest 3.00%
Show more

Is Lipocine, Inc. a top scorer stock according to the dividend, high growth investing or Leverman strategy?

As a free StocksGuide basic user, you can view the scores for all 6,953 shares worldwide.

Lipocine, Inc. Share analysis

Unlock scores for free

Analyst opinions

1 Analyst has issued a forecast Lipocine, Inc.:

1x Buy
100%

Analyst opinions

1 Analyst has issued a forecast Lipocine, Inc.:

Buy
100%

Financial data from Lipocine, Inc.

Profit and loss account P&L | Balance sheet | Cash flow


Quarter TTM Annually
Mar '24
+/-
%
7.67 7.67
1,295% 1,295%
100%
- Direct costs 0.03 0.03
200% 200%
0%
7.64 7.64
1,315% 1,315%
100%
- Selling and administrative expenses 5.16 5.16
26% 26%
67%
- Research and development costs 9.86 9.86
1% 1%
129%
-7.38 -7.38
45% 45%
-96%
- Depreciation and amortization 0.03 0.03
200% 200%
0%
EBIT (operating result) EBIT -7.41 -7.41
44% 44%
-97%
Net profit -8.97 -8.97
19% 19%
-117%

Figures in millions USD.

Don't miss a thing! We will send you all news about the Lipocine, Inc. share directly to your mailbox free of charge.

If you wish, you can receive an e-mail every morning in time for breakfast containing all the stock news relevant to you.

Lipocine, Inc. Share News

Neutral
PRNewsWire
5 days ago
Met standard bioequivalence (BE) criteria Cmax, AUC0-t, and AUC 0- ∞ Ctrough criterion was met LPCN 1154 was well tolerated with no sedation or somnolence events observed On track for NDA filing, targeted by end of Q4 2024 SALT LAKE CITY , June 25, 2024 /PRNewswire/ -- Lipocine Inc. (NASDAQ: LPCN), a biopharmaceutical company leveraging its proprietary technology platform to augment therapeutic...
Neutral
PRNewsWire
20 days ago
SALT LAKE CITY , June 10, 2024 /PRNewswire/ -- Lipocine Inc. (NASDAQ: LPCN), a biopharmaceutical company, today announced that Phase 2 results on LPCN 1148 in cirrhosis were featured in a late breaking oral presentation at the European Association for the Study of Liver (EASL) Congress on Saturday, June 8, in Milan, Italy. The presentation "Intervention with oral LPCN 1148 improves sarcopenia a...
Neutral
InvestorPlace
about one month ago
One of the oldest maxims in investing is that higher risk produces greater returns. That maxim holds particularly true across penny biotech stocks.
More Lipocine, Inc. News

Company profile

Lipocine, Inc. is a clinical-stage biopharmaceutical company, which engages in the research and development for the delivery of drugs using proprietary delivery technology. The firm involves in applying oral drug delivery technology for the development of pharmaceutical products focusing on metabolic and endocrine disorders. It offers TLANDO, an oral testosterone replacement therapy. The company was founded in 2011 and is headquartered in Salt Lake City, UT.

Head office United States
CEO Mahesh Patel
Employees 17
Founded 2011
Website www.lipocine.com

Register for free

StocksGuide is the tool for easily finding, analyzing and monitoring shares. Learn from successful investors and make well-founded investment decisions. We make you a self-determined investor.

The Apple share at a glance with charts, current key figures, news and share analyses.
The best dividend stocks in the dividend top scorer list.
Stock analyses of the best stocks worldwide.
Build wealth now